Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.51 |
| ▸ | PI4KA | P42356 | 1/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4147396 | 0.92 | ADORA2A (0.43) | ADORA2AADORA2BPI4KAPI4K2BPI4K2A | |
| SCHEMBL4236084 | 0.83 | ADORA2A (0.71) | ADORA2AADORA2BPI4KAPI4K2BPI4K2A | |
| SCHEMBL3876664 | 0.83 | ADORA2A (0.71) | ADORA2AADORA2BPI4KAPI4K2BPI4K2A | |
| SCHEMBL23922248 | 0.81 | PI4KA (0.66) | ADORA2AADORA2BPI4KAPI4K2BPI4K2A | |
| SCHEMBL22393148 | 0.81 | PI4KA (0.66) | ADORA2AADORA2BPI4KAPI4K2BPI4K2A | |
| SCHEMBL29703062 | 0.81 | PI4KA (0.66) | ADORA2AADORA2BPI4KAPI4K2BPI4K2A | |
| SCHEMBL11685537 | 0.81 | PI4KA (0.66) | ADORA2AADORA2BPI4KAPI4K2BPI4K2A | |
| SCHEMBL22402618 | 0.81 | PI4KA (0.66) | ADORA2AADORA2BPI4KAPI4K2BPI4K2A | |
| SCHEMBL26361515 | 0.81 | PI4KA (0.66) | ADORA2AADORA2BPI4KAPI4K2BPI4K2A | |
| SCHEMBL4145415 | 0.80 | ADORA2A (0.58) | ADORA2AADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | HPRT1, APRT, NUDT1 | ADORA2A 33/4885ADORA2B 46/4885PI4KA 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.